BTG3 Inhibitors
Chemical inhibitors of BTG3 can exert their inhibitory effects through the modulation of various cellular signaling pathways that BTG3 is known to interact with. Curcumin can functionally inhibit BTG3 by interfering with its role in cell cycle regulation, particularly through the alteration of cyclin-dependent kinase (CDK) activity, which BTG3 is implicated in regulating. Similarly, Kenpaullone can inhibit BTG3 by preventing its association with CDKs, thereby obstructing BTG3's regulatory effects on the cell cycle and transcription. Compounds such as PD98059 and U0126, both inhibitors of MEK, can inhibit BTG3 by blocking the MEK/ERK pathway, affecting BTG3's regulatory roles and consequently its cellular functions related to proliferation and differentiation. Resveratrol's action on the SIRT1 signaling pathway, which is involved in cell survival and apoptosis, can also inhibit the functional interaction of BTG3 with this pathway, further inhibiting BTG3's role in these processes.
Inhibition of the PI3K/Akt signaling pathway by LY294002 and Wortmannin can indirectly inhibit BTG3 by affecting cell growth, a process that BTG3 can influence. Rapamycin, by disrupting the mTOR signaling pathway, affects BTG3's involvement in cellular processes such as growth and proliferation that mTOR regulates. SP600125, a JNK inhibitor, and SB203580, a p38 MAPK inhibitor, can inhibit BTG3 by disrupting their respective signaling pathways-the JNK and p38 MAPK pathways-both of which involve BTG3 in stress response regulation. Additionally, KN-93 inhibits BTG3 by interfering with the calcium signaling pathway, where BTG3 is known to be involved through CaMKII activity. Finally, Gö 6983, a PKC inhibitor, blocks the PKC-mediated signaling pathways, which could lead to the functional inhibition of BTG3 in various cellular processes regulated by PKC.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin can functionally inhibit BTG3 by interfering with its role in cell cycle regulation. Curcumin is known to alter the activity of cyclin-dependent kinases (CDKs), and since BTG3 is implicated in CDK regulation, curcumin's effect on CDKs can indirectly inhibit BTG3's function in cell cycle control. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol can inhibit BTG3 by modulating the SIRT1 signaling pathway, which is involved in cell survival and apoptosis. BTG3 has been shown to interact with components of the cell survival pathway; resveratrol's action on SIRT1 can thus inhibit the functional interaction of BTG3 with this pathway. | ||||||
Kenpaullone | 142273-20-9 | sc-200643 sc-200643A sc-200643B sc-200643C | 1 mg 5 mg 10 mg 25 mg | $61.00 $153.00 $231.00 $505.00 | 1 | |
Kenpaullone, a CDK inhibitor, can inhibit BTG3 by preventing its association with CDKs, which is necessary for BTG3 to exert its regulatory effects on the cell cycle and transcription. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, can inhibit BTG3 by disrupting the JNK signaling pathway. As BTG3 has been implicated in stress response pathways that involve JNK, inhibition of JNK can indirectly inhibit BTG3's function in these pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, an inhibitor of MEK, can functionally inhibit BTG3 by blocking the MEK/ERK pathway. BTG3 has a role in the regulation of this pathway, and its inhibition can therefore affect BTG3's function related to cell proliferation and differentiation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K inhibitor, can functionally inhibit BTG3 by disrupting the PI3K/Akt signaling pathway. Since BTG3 can influence processes modulated by PI3K/Akt, such as cell growth, LY294002's inhibition of this pathway can indirectly inhibit the function of BTG3. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, a p38 MAPK inhibitor, can inhibit BTG3 by disrupting the p38 MAPK pathway. BTG3 is known to be involved in cellular stress responses that are regulated by p38 MAPK, and its inhibition can therefore affect BTG3's functional role. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a PI3K inhibitor, can inhibit BTG3 by blocking the PI3K/Akt pathway. This pathway is involved in several processes that BTG3 can regulate, and the inhibition by wortmannin can thus indirectly inhibit BTG3's function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, can inhibit BTG3 by disrupting the mTOR signaling pathway. Since BTG3 is involved in cellular processes such as growth and proliferation that mTOR regulates, rapamycin's inhibition of mTOR can indirectly inhibit BTG3. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
KN-93, an inhibitor of CaMKII, can inhibit BTG3 by interfering with the calcium signaling pathway. BTG3 is known to be involved in pathways where CaMKII plays a role, and its inhibition by KN-93 can therefore inhibit BTG3's function. | ||||||